Detail akcie Valneva SE online

Business Summary: Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Valneva SE revenues decreased 57% to EUR153.7M. Net loss decreased 29% to EUR101.4M. Revenues reflect COVID segment decrease of 98% to EUR7.7M, Vaccine Candidates segment decrease of 51% to EUR2.7M, United Kingdom segment decrease of 89% to EUR20.3M, Germany segment decrease of 80% to EUR13.5M. Lower net loss reflects Research and development expenses - Bala decrease of 44% to EUR56.9M (expense).